文献速递肿瘤 PET/CT甲状腺核医学

原发性前列腺癌中PSMA表达多样性:[68Ga]Ga-PSMA PET/CT阴性扫描的原因?40例手术标本的免疫组化验证

Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-05-12

该研究对40例初诊未治疗前列腺癌患者术前行[68Ga]Ga-PSMA I&T PET/CT,术后对原发肿瘤行PSMA免疫组化并计算免疫反应评分(IRS),与影像进行相关性分析。结果显示83%(33/40)患者原发灶至少一个前列腺叶有局灶摄取,PET阳性与阴性叶中位IRS均为2,但四分位距不同(2-3 vs 2-2,p=0.03);PET阳性肿瘤中位体积5.4 mL vs 阴性1.6 mL(p<0.001);PSMA阳性细胞≥90%的叶中35/44(约80%)PET阳性,而<90%的叶中19/36(约53%)PET阴性。结论认为原发灶PET阳性由PSMA表达均匀性、强度、肿瘤体积和分级共同决定,≥90% PSMA阳性细胞截断值强烈决定PET阳性。

要点

  • 83%(33/40)患者原发灶至少一个前列腺叶有[68Ga]Ga-PSMA I&T局灶摄取。
  • PET阳性与阴性前列腺叶中位IRS均为2,四分位距分别为2-3与2-2(p=0.03)。
  • PSMA阳性细胞≥90%的叶中35/44(约80%)PET阳性,<90%的叶中19/36(约53%)PET阴性。

核心结论

  • 原发灶[68Ga]Ga-PSMA I&T PET/CT阳性由PSMA表达均匀性和强度、肿瘤体积及分级共同决定,≥90% PSMA阳性细胞截断值强烈决定PET阳性。
  • 原发灶[68Ga]Ga-PSMA局灶聚集可能与前列腺癌侵袭性正相关,伴区域淋巴结受累和远处转移风险较高。

研究设计与样本

  • 研究纳入40例新诊断、未治疗的前列腺癌患者,术前诊断评估中行[68Ga]Ga-PSMA I&T PET/CT,随后行根治性前列腺切除术。
  • 所有原发肿瘤常规行H&E染色,并行PSMA免疫组化染色,计算免疫反应评分(IRS)作为半定量指标,并将影像结果与组织病理结果进行相关性分析。

主要发现

  • 83%(33/40)患者原发肿瘤至少一个前列腺叶出现[68Ga]Ga-PSMA I&T局灶摄取。
  • PSMA-PET阳性患者中三分之一经术后病理检出淋巴结转移,而PET阴性患者中7例仅1例有区域淋巴结受累。
  • PSMA-avid远处病灶(主要位于骨)在PET阳性与阴性患者中分别观察到15%和0%。
  • 肿瘤组织PSMA表达的IRS中位分类在PSMA-PET阳性和阴性前列腺叶均为2(范围1-3),四分位距分别为2-3和2-2(p=0.03)。
  • PSMA-PET阳性肿瘤中位体积为5.4 mL(0.2-32.9),PET阴性肿瘤为1.6 mL(0.3-18.3)(p<0.001);SUVmax与PSMA阳性肿瘤细胞百分比呈显著但弱相关(r=0.46,p<0.001)。

关键数值与推荐

  • 当PSMA阳性细胞百分比截断值为≥90%时,35/44(约80%)前列腺叶在PSMA-PET显像中为阳性;而PSMA阳性细胞<90%的36个叶中19个(约53%)为PSMA-PET阴性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to immunohistochemically validate the primary tumor PSMA expression in prostate cancer (PCa) patients imaged with [68Ga]Ga-PSMA PET/CT prior to surgery, with special consideration of PET-negative cases. METHODS: The study included 40 men with newly diagnosed treatment-naïve PCa imaged with [68Ga]Ga-PSMA I&T PET/CT as part of the diagnostic work-up prior to radical prostatectomy. All primary tumors were routinely stained with H&E. In addition, immunohistochemical staining of PSMA was performed and the immunoreactive score (IRS) was computed as semiquantitative measure. Subsequently, imaging findings were correlated to histopathologic results. RESULTS: Eighty-three percent (33/40) of patients presented focal uptake of [68Ga]Ga-PSMA I&T in the primary tumor in at least one prostate lobe. Among PSMA-PET positive patients, one-third had lymph node metastases (LNM) detected by post-operative histopathology, while in PET negative patients, only 1 out of 7 presented with regional LN involvement; PSMA-avid distant lesions, predominantly in bones, were observed in 15% and 0% of patients, respectively. The median IRS classification of PSMA expression in tumor tissue was 2 (range, 1-3) both in PSMA-PET positive and negative prostate lobes, with significantly different interquartile range: 2-3 vs. 2-2, respectively (p = 0.03). The median volume of PSMA-PET positive tumors was 5.4 mL (0.2-32.9) as compared to 1.6 mL (0.3-18.3) of PET-negative tumors (p < 0.001). There was a significant but weak correlation between SUVmax and percentage of PSMA-positive tumor cells (r = 0.46, p < 0.001). A total of 35/44 (~80%) lobes were positive in PSMA-PET imaging, when a cut-off percentage of PSMA-positive cells was ≥ 90%, while 19/36 (~53%) lobes with < 90% PSMA-positive cells were PSMA-PET negative. CONCLUSION: Positive [68Ga]Ga-PSMA I&T PET/CT scan of primary tumor of PCa results from a combination of factors, such as homogeneity and intensity of PSMA expression, tumor volume and grade, with a cutoff value of ≥ 90% PSMA-positive cells strongly determining PET-positivity. Focal accumulation of [68Ga]Ga-PSMA in the primary tumor may correlate positively with aggressiveness of prostate cancer, harboring higher risk of regional LN involvement and distant metastatic spread.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cytawa W, Kircher S, Kübler H, et al. Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens. Eur J Nucl Med Mol Imaging. 2022. PMID: 35556160. doi:10.1007/s00259-022-05831-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。